Healthcare -
Biotechnology - NASDAQ - US
$ 7.77
-5.08 %
$ 459 M
Market Cap
-2.82
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Cullinan Oncology, Inc.
| Revenue | 0 |
| Cost Of Revenue | 306 K |
| Gross Profit | -306 K |
| Operating Expenses | 197 M |
| Operating Income | -197 M |
| Other Expenses | -29.3 M |
| Net Income | -168 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 0 | 0 | 0 | 18.9 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 0.3 | 0.3 | 93 K | 53 K | 62 K | 70 K | 43 K |
| Gross Profit | (0.3) | (0.3) | 93 K | 18.9 | 62 K | 70 K | 43 K |
| OPERATING INCOME | |||||||
| Operating Expenses | 196.6 | 191.1 | 132.1 | 86.9 | 60.3 | 22.3 | 14.6 |
| Selling, General and Administrative Expenses | 53.7 | 42.5 | 40.2 | 29.1 | 17.1 | 5.5 | 5.0 |
| Research and Development Expenses | 142.9 | 148.2 | 91.9 | 57.8 | 43.2 | 16.8 | 9.6 |
| Operating Income | (196.9) | (191.1) | 144.6 | (68.0) | (60.3) | (22.3) | (14.6) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 29.5 | 21.9 | 6.7 | 0.5 | 0.9 | 0.6 | 0.4 |
| Pre-Tax Income | (167.5) | (169.2) | 151.3 | (67.5) | (59.5) | (21.7) | (14.2) |
| NET INCOME | |||||||
| Tax Provision | 0.1 | (14.1) | 42.1 | (2.4) | (8.6) | (1.6) | 0.4 |
| Net Income | (167.4) | (153.2) | 111.2 | (65.0) | (50.8) | (20.0) | (14.2) |
| EPS | 3.11 | 3.69 | 2.46 | 1.47 | 1.17 | 0.46 | 1.24 |